GVK BIO Announces USFDA Approval for its cGMP Analytical Services Laboratory

The company received No Action Indicated (NAI) compliance status with zero 483 observations from the USFDA which signifies compliance and conformance to applicable cGMP regulations.
According to Mr. Manni Kantipudi, Director & CEO GVK BIO, “The USFDA clearance with zero 483 observations and the NAI is a testimony to GVK BIO’s commitment to global standards of quality and compliance. At GVK BIO, ‘Safety, Quality and Compliance’ come before Business and Quality is given the highest priority. In addition to the USFDA accreditation the facility has an ISO 17025 NABL accreditation, CDSCO/DCA Approval, FEI# 3011573185 and DUNS number- 650953990.”

GVK BIO offers a range of Formulations & Analytical Solutions that include pre-formulation development, formulation development, analytical R&D, reformulation, stability studies, clinical supplies and manufacturing of exhibit batches.

Our expertise in Analytical Solutions address the most complex challenges right from research, chemical, analytical to quality control in the drug development process.

Our Analytical Solutions include, analytical method development, validations & optimization, identification and isolation of trace level impurities, method development & quantification of genotoxic impurities and trace elemental, characterization of polymorphs/pseudo polymorphs, stability studies, dissolution profile, particle size distribution analysis, extractable and leachable Studies and Microbiology .We also perform stability analysis of drug products and active ingredient (APIs), packaging as per ICH, quality control testing and release as per cGMP requirements.